semaglutide pdufa date FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Upcoming FDA Approvals: New Drugs

GLP-1 receptor agonists have transformed weight loss treatment over the past decade, with clinical trials showing average weight reductions of 15-22% depending on the medication and dose

Schedule Lab Testing Maximize your health benefits by combining services for enhanced results and additional savings Perfect for sustained energy and immune support Learn More Comprehensive care for optimal health maintenance Learn More Don't let fatigue control your life

Yamada H, Fujimoto M, Svay S, Lim O, Hok S, Goto N, et al

doi: 10.1038/s41440-020-0402-8

It's whether the research question justifies the added complexity

While the new guidance could open the door for broader coverage of GLP-1s that secure additional indications, it would not extend Part D coverage to these therapies to address obesity on its own, according to the article